Trial reportLeukemia2018
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph
Trial report in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Pooled it
- Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.Blood advances · 2019Trial
- Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.Leukemia · 2026Article
- Article
- Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.Leukemia · 2025Article
- Clonal hematopoiesis in AML long-term survivors: Risk factors and clinical consequences.HemaSphere · 2025Article
- Histamine dihydrochloride and low-dose interleukin-2 has anti-leukemic efficacy in <i>NPM1</i>-mutated and myelomonocytic/monocytic acute myeloid leukemia.Haematologica · 2024Article
- Friday Leukemia-a Structural Phenomenon.Deutsches Arzteblatt international · 2024Article
- Improving long-term outcomes with intensive induction chemotherapy for patients with AML.Hematology. American Society of Hematology. Education Program · 2023Article
- Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Leukemia · 2023Article
- Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles.Communications medicine · 2023Article
- Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.Journal of hematology & oncology · 2022Article
- Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis.Annals of hematology · 2022Article
- Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy.Blood advances · 2022Article
- Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia.Haematologica · 2022Article
- Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.Blood advances · 2022Article
- Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears.Leukemia · 2022Article
- Fusion gene detection by RNA-sequencing complements diagnostics of acute myeloid leukemia and identifies recurringHaematologica · 2022Article
- A clinically applicable gene expression-based score predicts resistance to induction treatment in acute myeloid leukemia.Blood advances · 2021Article
- Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Leukemia · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 20 institutions in 2 countries.
Jan BraessDepartment of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany. Jan.Braess@barmherzige-regensburg.de.
Susanne AmlerInsitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany.
Karl-Anton KreuzerDepartment of Internal Medicine I, University Hospital, Cologne, Germany.
Karsten SpiekermannDepartment of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.
Hans Walter LindemannDepartment of Hematology and Oncology, Catholic Hospital, Hagen, Germany.
Eva LengfelderDepartment of Medicine III, University Hospital, Mannheim, Germany.
Ullrich GraevenDepartment of Medicine I, Hospital Maria Hilf, Mönchengladbach, Germany.
Peter StaibDepartment of Hematology and Medical Oncology, St. Antonius Hospital, Eschweiler, Germany.
Wolf-Dieter LudwigDepartment of Hematology and Oncology and Tumor Immunology, Helios Hospital, Berlin-Buch, Germany.
Harald BiersackDepartment of Medicine I, University Hospital, Lübeck, Germany.
Yon-Dschun KoDepartment of Medicine I, Johanniter Hospital, Bonn, Germany.
Michael J UppenkampDepartment of Medicine A, Klinikum Ludwigshafen, Ludwigshafen, Germany.
Maike De WitDepartment of Hematology, Oncology and Palliative Care, Vivantes Klinikum Neukölln, Berlin, Germany.
Stefan KorstenDepartment of Medicine, Vinzenz Pallotti Hospital, Bergisch-Gladbach, Germany.
Rudolf PecenyDepartment of Hematology and Oncology, Klinikum Osnabrück, Osnabrück, Germany.
Tobias GaskaDepartment of Hematology and Oncology, St. Josef Hospital, Paderborn, Germany.
Xaver SchielDepartment of Hematology and Oncology, Klinikum Harlaching, Munich, Germany.
Dirk M BehringerDepartment of Hematology, Oncology and Palliative Care, Augusta Hospital, Bochum, Germany.
Michael G KiehlDepartment of Medicine I, Klinikum Frankfurt/Oder, Frankfurt/Oder, Germany.
Bettina ZinngrebeDepartment of Hematology, Oncology and Palliative Care, Evangelisches Krankenhaus, Bielefeld, Germany.
Gerald MeckenstockDepartment of Medical Oncology, Radiooncology, Hematology and Palliative Care, St. Josef Hospital, Gelsenkirchen, Germany.
Eva RoemerDepartment of Hematology and Oncology, Klinikum Idar-Oberstein, Idar-Oberstein, Germany.
Dirk MedgenbergDepartment of Medicine III, Klinikum Leverkusen, Leverkusen, Germany.
Ernst Spaeth-SchwalbeDepartment of Medicine, Vivantes Klinikum Spandau, Berlin, Germany.
Gero MassenkeilDepartment of Medicine II, Klinikum Gütersloh, Gütersloh, Germany.
Heidrun HindahlDepartment of Medicine I, St. Johannes Hospital, Dortmund, Germany.
Rainer SchwerdtfegerDepartment for Bone Marrow and Blood Stem Cell Transplantation, DKD Deutsche Klinik für Diagnostik, Wiesbaden, Germany.
Guido TrennDepartment of Medicine I, Knappschaftskrankenhaus, Bottrop, Germany.
Cristina SauerlandInsitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany.
Raphael KochInsitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany.
Martin LablansInsitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany.
Andreas FaldumInsitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany.
Dennis GörlichInsitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany.
Stefan K BohlanderDepartment of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.
Stephanie SchneiderDepartment of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.
Annika DufourDepartment of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.
Christian BuskeDepartment of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.
Michael FieglDepartment of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.
Marion SubkleweDepartment of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.
Birgit BraessDepartment of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany.
Michael UnterhaltDepartment of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.
Anja BaumgartnerDepartment of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.
Bernhard WörmannGerman Society of Hematology and Oncology DGHO, Berlin, Germany.
Dietrich BeelenDepartment of Bone Marrow Transplantation, University Hospital, Essen, Germany.
Wolfgang HiddemannDepartment of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.
AML-CG
LMU Klinikum · DEUniversity Hospital Münster · DEVivantes Klinikum · DEArvato · DEDeutsche Klinik für Diagnostik · DEEvangelisches Krankenhaus Bielefeld · DEUniversity of Auckland · NZUniversity of Mannheim · DEAugusta-Kranken-Anstalt · DEBrüderkrankenhaus St. Josef Paderborn · DEDeutsche Gesellschaft für Hämatologie und Medizinische Onkologie · DEFriedrich-Loeffler-Institut · DEGerman Cancer Research Center · DEHelios Hospital Berlin-Buch · DEJohanniter-Krankenhaus Bonn · DEKliniken Maria Hilf · DEKlinikum Frankfurt Höchst · DEKlinikum Leverkusen · DEKlinikum Ludwigshafen · DEKlinikum Osnabrück · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dose-dense induction with the S-HAM regimen was compared to standard double induction therapy in adult patients with newly diagnosed acute myeloid leukemia. Patients were centrally randomized (1:1) between S-HAM (2nd chemotherapy cycle starting on day 8 = "dose-dense") and double induction with TAD-HAM or HAM(-HAM) (2nd cycle starting on day 21 = "standard"). 387 evaluable patients were randomly assigned to S-HAM (N = 203) and to standard double induction (N = 184). The primary endpoint overall response rate (ORR) consisting of complete remission (CR) and incomplete remission (CR
Indexed as
AdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCytarabineFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMitoxantroneRemission InductionYoung AdultCytarabineMitoxantrone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.